| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BeOne Medicines Ltd. | Dapirolizumab pegol - (PHOENYCS FLY) | Systemic Lupus Erythematosus | Phase 3 | Trial Planned | Intravenous | Immunology |
| BeOne Medicines Ltd. | Ociperlimab (BGB-A1217) - (AdvanTIG-302) | Non-small Cell Lung Cancer | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| BeOne Medicines Ltd. | Sonrotoclax (BGB-11417) | Waldenström's macroglobulinemia | Phase 2 | Ongoing | Oral | Hematology |
| BeOne Medicines Ltd. | BGB-16673-101 - (CaDAnCe-101) | Relapsed or refractory (R/R) CLL/SLL | Phase 2 | Enrollment Initiation | Oral | Oncology |
| BeOne Medicines Ltd. | Tislelizumab - (RATIONALE-208) | Hepatocellular carcinoma (HCC) - second-line | Phase 2 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | Sonrotoclax - (CELESTIAL-RRMCL) | Relapsed or refractory (R/R) mantle cell lymphoma (MCL) | Phase 3 | Ongoing | Intravenous | Oncology |
| BeOne Medicines Ltd. | Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) | First-line HER2-positive gastroesophageal adenocarcinoma (GEA) | Phase 3 | Data Released | Intravenous infusion | Oncology |
| BeOne Medicines Ltd. | Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) | First-line HER2-positive gastroesophageal adenocarcinoma (GEA) | Phase 3 | Data Released | Intravenous infusion | Oncology |